Welcome to our dedicated page for ASAHI KAISEI CRP UNSP/ADR news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on ASAHI KAISEI CRP UNSP/ADR stock.
Asahi Kasei Corporation (symbol: AHKSY) is a diversified Japanese technology and manufacturing company dedicated to contributing to life and living globally. Since its foundation in 1922 with ammonia and cellulose fiber businesses, Asahi Kasei has continuously transformed its business portfolio to meet evolving market demands. The company operates through three primary sectors: Material, Homes, and Health Care.
In the Material sector, Asahi Kasei produces a wide array of products, including battery separators, biodegradable textiles, engineering plastics, and sound solutions. Recently, the company announced a significant investment in an integrated plant in Ontario, Canada, for manufacturing Hipore™ wet-process lithium-ion battery separators, in partnership with Honda and the Development Bank of Japan.
In the Health Care sector, Asahi Kasei focuses on devices and systems for acute critical care, dialysis, therapeutic apheresis, and the manufacturing of biotherapeutics. The company recently completed the construction of its third assembly plant for Planova™ virus removal filters in Japan and announced the launch of a new plasmid DNA manufacturing facility in Texas, USA, through its subsidiary, Bionova Scientific.
Asahi Kasei is also making strides in the renewable energy sector with its hydrogen business. The company celebrated the opening of a new hydrogen pilot plant in Kawasaki, Japan, marking a significant milestone toward commercializing large-scale alkaline water electrolysis systems for green hydrogen production.
In addition to these advancements, Asahi Kasei is committed to sustainability, aiming to reach carbon neutrality by 2050. The company's R&D initiatives include the development of high ionic conductive electrolytes for lithium-ion batteries, which promise enhanced performance and durability at extreme temperatures.
Asahi Kasei's recent partnership with Axolabs to establish a cutting-edge oligonucleotide cGMP manufacturing facility in Berlin underscores its commitment to innovation in the biopharmaceutical industry. This collaboration aims to accelerate the development and commercialization of oligonucleotide-based therapies to improve patient quality of life globally.
With over 48,000 employees worldwide, Asahi Kasei continues to be a global leader in providing innovative solutions to the world's challenges, ensuring sustainable growth and development.
Asahi Kasei showcased their new AKXY2 concept car at CES 2023, emphasizing solutions for sustainable mobility. The vehicle features innovations like Active Road Noise Cancellation, millimeter-wave radar for child detection, and drunk driving prevention systems. The company highlighted its commitment to sustainability, integrating recycled materials and advanced technologies in the automotive sector. AKXY2 proposes a 'mobile living space' concept, aligning with modern consumer demands for comfort and eco-friendliness.
Asahi Kasei has announced the sale of Tufdene™ S-SBR and Asadene™ BR, produced using the mass-balance method, starting November 2022. The products, certified under ISCC PLUS, aim to meet the growing demand for sustainable materials, particularly for eco-friendly tires. Asahi Kasei plans to reduce CO2 emissions by integrating biomass and plastic waste in production. The company seeks to become a sustainable partner for customers while striving for carbon neutrality by 2050.
Asahi Kasei has acquired ISCC PLUS certification for several products, allowing it to manage biomass and recycled materials using the mass-balance method across its supply chain. The certified products include Acrylonitrile, Methyl methacrylate, and various types of rubber and plastic. This certification aligns with the company’s commitment to sustainability and carbon neutrality, enhancing its product offerings to meet global demands for eco-friendly solutions. Asahi Kasei aims to deepen collaboration with partners and further its sustainability goals.
Asahi Kasei has begun constructing an alkaline water electrolysis pilot test plant for hydrogen production at its Kawasaki Works in Japan, expected to commence operations in early 2024. This project, supported by Japan's NEDO, aims to enhance the efficiency of electrolysis equipment to adapt to renewable energy power fluctuations. With a focus on hydrogen as a strategic growth area, Asahi Kasei plans to commercialize larger alkaline water electrolysis systems by 2025, building on its previous trials since 2020.
Asahi Kasei Pharma is inviting proposals for drug development research, offering funding of up to US$200,000 annually for selected applications over a period of 1-3 years. The application window runs from January 5, 2023 to February 28, 2023. The focus areas include autoimmune, renal, neurodegenerative, and bone diseases, alongside platform technologies for drug discovery. Established in 2016, Asahi Kasei Pharma has funded over 20 proposals and aims to foster innovation through collaborations with global researchers.
Asahi Kasei and Crystal IS have reported that their experimental Klaran™ WR UVC LED water treatment reactor outperformed traditional mercury lamp systems by over 75% in bacterial performance tests. The reactor operates at the same power level (6 W) while being lighter, smaller, and safer, contributing to a mercury-free environment. This advancement aligns with the stricter regulations following the Minamata Convention, promoting energy efficiency and safer water treatment. Asahi Kasei aims to replace mercury lamps with UVC LEDs in various applications.
Asahi Kasei is launching new grades of XYRON™ modified polyphenylene ether (mPPE) to enhance 5G applications in North America and Europe. These materials offer improved connectivity, lighter weight, and higher heat resistance than traditional metals. Key features include low dielectric permittivity and high hydrolysis resistance, resulting in better efficiency for 5G smartphone antennas and base stations. The new recycled PET/PPE alloys utilize 40% post-consumer materials, supporting sustainability. XYRON™ will be showcased at K 2022 in Düsseldorf from October 19-26.
Asahi Kasei has announced a trial to test its K-GIS zeolite adsorbent for purifying biogas at Kurashiki City's sewage treatment plant. The System aims to efficiently separate CO2 from biogas, generating high-purity biomethane. Aiming for operational launch by the end of 2023, the project aligns with the company's carbon neutrality goals. The partnership with Kurashiki City emphasizes the importance of decarbonization. If effective, this technology could lead to a carbon-negative cycle through carbon capture, utilization, or storage.
FAQ
What is the current stock price of ASAHI KAISEI CRP UNSP/ADR (AHKSY)?
What is the market cap of ASAHI KAISEI CRP UNSP/ADR (AHKSY)?
What sectors does Asahi Kasei operate in?
What recent projects has Asahi Kasei announced?
What is Asahi Kasei's commitment to sustainability?
Who are Asahi Kasei's key partners in recent ventures?
What are Asahi Kasei's contributions to the biopharmaceutical industry?
Where is Asahi Kasei's new hydrogen pilot plant located?
What is the Hipore™ wet-process separator used for?
How does Asahi Kasei support innovation in manufacturing?
What are the benefits of Asahi Kasei's high ionic conductive electrolyte?
How many employees does Asahi Kasei have globally?
